A 58-year-old woman presents with a 4-week history of rapid enlargement of a mass in the left parotid region, accompanied by pain, facial nerve paralysis (House-Brackmann Grade III), and skin erythema. Ultrasound shows a heterogeneous, hypoechoic mass with ill-defined margins. FNAC reveals malignant cells consistent with mucoepidermoid carcinoma. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has a malignant parotid tumor (mucoepidermoid carcinoma) with aggressive features: rapid growth, pain, facial nerve involvement (Grade III paralysis), and skin changes. These indicate advanced local disease requiring comprehensive staging and multimodal therapy planning. ## Why Staging Before Treatment Planning? **Key Point:** Malignant salivary gland tumors require complete staging to: - Determine TNM stage and prognosis - Identify distant metastases (lungs, bones, liver) - Plan the extent of surgery (superficial vs. total parotidectomy, facial nerve sacrifice, neck dissection) - Determine need for adjuvant radiation and/or chemotherapy - Guide patient counseling on outcomes **High-Yield:** The imaging modality of choice for parotid malignancy is **MRI** because it: 1. Provides superior soft-tissue contrast for tumor extent 2. Assesses facial nerve involvement and perineural spread 3. Evaluates deep lobe and skull base involvement 4. Detects cervical lymph node metastases **Clinical Pearl:** Facial nerve paralysis in a parotid tumor is a sign of malignancy until proven otherwise. It indicates nerve invasion and necessitates nerve sacrifice during surgery. Preoperative imaging must confirm perineural spread. ## Staging Investigations **Mnemonic:** **STAMP** = **S**taging MRI, **T**omography (CT chest/abdomen), **A**dvanced imaging (PET-CT for high-grade tumors), **M**ultimodal planning, **P**roceed to surgery. | Investigation | Purpose | |---|---| | **MRI parotid** | Local tumor extent, facial nerve invasion, deep lobe involvement | | **CT chest/abdomen** | Detect pulmonary and hepatic metastases | | **PET-CT** | Identify distant metastases; particularly useful for high-grade tumors (mucoepidermoid is often intermediate-to-high grade) | | **Neck ultrasound ± CT** | Cervical lymph node staging | ## Why Not Immediate Surgery? **Warning:** Proceeding directly to surgery without staging risks: - Incomplete resection if distant metastases are present - Unnecessary morbidity from extensive surgery if patient is palliative - Missed opportunity to tailor adjuvant therapy - Inadequate prognostic information ## Treatment Algorithm ```mermaid flowchart TD A[Malignant parotid tumor + facial nerve involvement]:::outcome --> B[MRI parotid + CT chest/abdomen + PET-CT]:::action B --> C{Staging complete?}:::decision C -->|Yes| D[Multidisciplinary team discussion]:::action D --> E{Resectable + no distant mets?}:::decision E -->|Yes| F[Wide parotidectomy ± facial nerve sacrifice + neck dissection]:::action E -->|No| G[Palliative chemoradiation]:::action F --> H[Adjuvant radiation ± chemotherapy based on grade/margins]:::action G --> I[Symptom management]:::action ``` ## Why Not the Other Options? | Option | Why Incorrect | |--------|---------------| | Palliative chemo + RT first | Skips staging; assumes unresectable disease without evidence; upfront chemotherapy is not standard for resectable malignancy | | CT chest/abdomen only (no MRI, no PET) | Omits MRI, which is superior for local tumor extent and facial nerve assessment; PET-CT is indicated for intermediate-to-high-grade tumors to detect distant metastases | | Immediate wide parotidectomy | Violates surgical oncology principles: operate without complete staging; risks incomplete resection if metastases exist; denies patient benefit of adjuvant therapy planning |